Objective. To evaluate the efficacy and safety of a homeopathic gel vs an NSAID (piroxicam) gel in the treatment of osteoarthritis of the knee.
Mild to moderate osteoarthritis is often treated with of topical NSAIDs [7] concluded that these products are effective in relieving pain. non-steroidal anti-inflammatory drugs (NSAIDs). However, treatment with oral NSAIDs is not always Hahnemann, the founder of homeopathy, first suggested the possibility of administering homeopathic effective and may have significant side-effects [1] [2] [3] . As a safe alternative to oral NSAIDs, a number of topical medicines via the skin [8] . Recently, the topical administration of homeopathic medicines has rapidly gained in NSAIDs are now available in many countries and their use is increasing: in the UK alone, £33 million (approxipopularity. In The Netherlands, SRLB (current trade name Spiroflor SRLB; the trade name is used because mately US$50 million) was spent on prescribed topical NSAIDs in 1997 (Prescription Pricing Authority data).
SRLB gel does not have a chemical name or an international non-proprietary name), a gel containing three Apart from this, the over-the-counter market for topical NSAIDs is growing rapidly. Between June 1996 and homeopathic ingredients, is one of the topical antirheumatic preparations most frequently prescribed June 1997 more than 15 million tubes were sold in the UK alone, a growth of 43% over the previous year by Dutch general practitioners [9, 10] . Very similar products are on the market in several European coun-(Institute for Medical Statistics, UK ). For a long time, evidence of the efficacy of topical NSAIDs was incontries and in the USA (e.g. TrifloraB gel ). However, evidence of efficacy from rigorous, controlled trials is clusive [4] [5] [6] . Recently, a quantitative systematic review lacking. We conducted a pragmatic, randomized, double-blind controlled trial comparing SRLB gel with piroxicam gel in osteoarthritis of the knee. The main compare the efficacy and safety of SRLB and piroxicam treated and evaluated. Treatment compliance was estimgel and to establish the clinical relevance of the observed ated by weighing returned tubes of study medication. effects. Analysis was according to the latest principles Paracetamol up to 3 g per day was allowed as a rescue laid down for equivalence trials [11] . This analytical analgesic. Oral NSAIDs and any other medication were approach was adopted after the trial was completed but continued during the trial. Patients were not given prior to commencement of the analyses. A 'per protocol' specific additional instructions with regard to exercise, compliers-only analysis was specified a priori. No specific restriction of activities, etc. covariate analyses were defined a priori.
Primary outcome measures were pain on walking during the previous 24 h, recorded on a 100 mm Visual Analogue Scale ( VAS ) [13] , and pain on palpation of Methods the affected knee, scored according to Ritchie et al. [14] (0 = no pain, 1 = pain without wincing, 2 = pain with Protocol wincing, 3 = pain leading to withdrawal ). Secondary Patients were recruited and treated at the out-patients outcome measures were the number of paracetamol rheumatology clinic of St Bartholomew's Hospital and tablets (rescue analgesic) used and an overall assessment also recruited from St Leonard's and Homerton by the investigator and the patient on a six-point scale Hospitals, London. Eligibility criteria are listed in ('worse than useless', 'useless', 'poor', 'fair', 'good', Table 1 . Previous use of SRLB gel was not an exclusion 'excellent'). Patients also completed a weekly score on criterion because it was not available on the UK market. a 100 mm VAS indicating relief obtained during the The radiographic confirmation of the diagnosis was preceding week. based on a report by an independent radiologist of an Based on the literature available on piroxicam gel at X-ray of the knees within the previous 6 months. The the time of protocol development, the recruitment target radiological criteria for diagnosis of osteoarthritis were was set at 225 patients in order to obtain about 200 narrowing of the joint space and/or the presence of patients with outcome data (similar to n in the largest osteophytes or tibial spiking, with or without effusion.
piroxicam gel trial ). A formal power calculation was Demographic and baseline data collected were age, not conducted because of the complete absence of data sex, weight, pain in the knee on movement (moderate/ on the effect of treatment on VAS when the study was severe), information regarding other illnesses, and use designed. of other drugs for osteoarthritis and other conditions. Patients were seen twice for the purpose of this trial: at Because the use of a single-joint Ritchie score for recruitment/baseline and after 4 weeks of treatment.
osteoarthritis is uncommon, it was not possible to define There were no prospectively defined stopping rules. a minimum clinically important difference. Based on the SRLB gel contains the homeopathic ingredients literature [15] and consensus in the Department of Symphytum officinale (comfrey), Rhus toxicodendron Rheumatology at St Bartholomew's Hospital, 5 mm on (poison ivy) and Ledum palustre (marsh-tea). It a VAS for pain on walking was defined as a minimum was manufactured by VSM Geneesmiddelen ( The clinically important difference (equivalence range: Netherlands) in accordance with the official German −5 mm to +5 mm) prior to the initiation of the anaHomeopathic Pharmacopoeia [12] . Piroxicam gel lyses. Analysis of the VAS data was based on the latest (FeldeneB) contains 0.5% piroxicam and was manufacavailable guidelines for the analysis of equivalence trials tured by Pfizer Ltd UK. [11] , which involves the use of 95% confidence intervals Patients were instructed to apply approximately 1 g in relation to the equivalence range. To enable the use of gel three times daily. For application, a spatula with of confidence intervals, the population with a follow-up a sticker indicating the length of approximately 1 g of measurement (endpoint) was used. All other main anagel was supplied. If both knees were affected, only the lyses of outcome were based on the intention-to-treat knee with the most clinically evident osteoarthritis was population (all patients randomized), using the convention that missing values assume the worst possible outcome. entry and logical checks. Statistical analyses were conducted using SPSS for Windows version 7.0 (SPSS Inc., USA). Statistical testing was two-tailed.
Assignment
The unit of randomization was individual patients entered. Treatment allocation was based on randomization in blocks of four using randomization software (RCODE version 3.4, Schwabe, Germany) at the Research Department of VSM Geneesmiddelen. A special randomization list was printed to allow the treatment code to be broken for individual patients in exceptional circumstances. Treatment assignment was done at inclusion by the clinical metrologist, and was based on the lowest unused randomization number. Both products are carbomer-based gels of similar consistency, but they differ in appearance and smell: SRLB gel is brownish in colour (due to the tinctures for Analysis external use) and has a characteristic odour (due to the Due to local administrative problems, recruitment addition of pine oil ). Because it was intrinsically imposssuffered such delays that it was decided to stop the trial ible to make both treatments identical, or to use the after184 patients had enrolled. One hundred and sevdouble-dummy technique, the original SRLB (80 g) and enty-two patients had endpoints for the main outcome piroxicam (60 g) tubes were used. Masking was achieved parameters. Three patients had violations of the eligibilby sealing the tubes in a double layer of opaque blue ity criteria: one was 87 years old, in one there was no plastic. The standard blue ribbed caps of piroxicam gel radiographic confirmation of osteoarthritis, and one was tubes were replaced by white caps of a different shape not stable on oral NSAIDs. and size. The patient received a sealed, numbered box Baseline characteristics were similar in the two treatcontaining the study medication and rescue analgesics ment groups ( Table 2) . 180 patients returned the tubes and was instructed to open it only on returning home, with study medication. Daily gel use was 3.3 g in the making sure the clinical metrologist did not see its SRLB group and 2.7 g in the piroxicam group, an contents. Treatment masking was broken for each average treatment compliance of 110% (95% confidence patient, after all other measurements had taken place, interval 99-121) in the SRLB group and 90% (95% when the clinical metrologist checked whether the study confidence interval 83-97) in the piroxicam group. Fiftydrugs and all strips of used and unused rescue analgesics seven patients (64%; 26% <80% compliance + 38% were returned. There were no differences in expected >120% compliance) in the SRLB group and 51 (56%; drug (side) effects which could have affected masking. 40% <80% compliance+16% >120% compliance) in Discussion between subjects was unlikely: patients did the piroxicam group were outside the prespecified comnot know which other patients had been included in the pliance range of 80-120%. This indicates that SRLB study and were given separate (only one) follow-up patients tended to be overcompliant and piroxicam appointments. A sealed full randomization list and the patients undercompliant. special list enabling individual code-breaks was available at St Bartholomew's Hospital.
The treatment codes were not broken for any patient. In total, nine patients (six SRLB, three piroxicam) (25-75 percentiles) discontinued the trial (Fig. 1) . In three patients on (Fig. 2) . A full
The overall assessments of the usefulness of the study factorial analysis of covariance took place, including the gel by the investigator and patient are given in Table 3 . potential confounders 'tablets rescue analgesics taken ' The x2 test for the investigator assessment yielded (F = 0.18; P = 0.67) and 'pain at baseline' (F = 26.6; P = 0.19. The x2 test for the patient assessment yielded P = 0.00) after model validity had been confirmed. In P = 0.06. The subset with an endpoint yielded similar a stepwise procedure 'tablets rescue analgesics taken' results: P = 0.27 for the investigator and P = 0.05 for was removed. The difference between treatment groups the patients. In the investigator endpoint table, four adjusted for pain at baseline was 6.8 mm (95% confidcells (33.3%) have an expected count of <5, which ence interval −0.3 to 13.8). This confidence interval did means that the corresponding P-value may not be not lie entirely inside the equivalence range (− 5 to +5), completely valid. These results indicate a trend in favour which means that the presence of a clinically relevant of SRLB gel. difference between the two treatments (i.e. superiority
Adverse events are summarized in Table 4 . Local of SRLB gel ) cannot be excluded. Additionally, the reactions to SRLB gel were generally mild, ranging from VAS reduction in the intention-to-treat population was transient itchiness around the site of application to analysed assuming the worst observed outcome transient burning sensations and redness. Local reac-(− 68 mm) for missing data. This meant that the distritions to piroxicam were similar to those to SRLB gel bution of the VAS outcome data was non-normal. but additionally three patients developed an itchy derTherefore the non-parametric Mann-Whitney U-test matitis in the area of application. One patient in the was used (mean rank, SRLB group 100.7; mean rank, piroxicam group developed a generalized itchy dermapiroxicam group 84.3, P = 0.036).
titis. In these four patients the relationship between the Changes in the single-joint Ritchie index ranged from adverse event and the study drug was rated as 'definite' −2 to +2. Results for the SRLB group were as follows:
by the rheumatologist.
Unexpectedly, a significant interaction was found (n = 6), including six missing values recoded to −2, the between the use of pain medication (oral NSAIDs worst possible outcome. Results for the piroxicam group and/or analgesics) and treatment. Between-treatment were as follows: −2 (n = 5), −1 (n = 15), 0 (n = 46), differences (adjusted for the VAS at baseline) were +1 (n = 19), +2 (n = 7), including five missing values 0.3 mm (in favour of SRLB) in the pain medication recoded to −2. There was no difference in the Ritchie users (n = 106; 55 SRLB, 51 piroxicam; 95% confidence index between treatment groups in the intention-to-treat interval −8.5 to 9.1) and 17.2 mm (in favour of SRLB) population (x2 test, P = 0.37) and in the subset with an in the non-users of pain medication (n = 66; 31 SRLB, endpoint ( x2 test, P = 0.159).
Fifty-six patients (61%) in the SRLB group (including 35 piroxicam; 95% confidence interval 5.9-28.4). appears to give subtherapeutic concentrations. If confirmed, this finding would remove one of the main Further analysis of the 170 patients for whom the exact nature of the pain medication could be established rationales for the use of NSAID gels, which is to avoid the systemic side-effects of oral NSAIDs. revealed that this difference was largely due to piroxicam gel being effective mainly in patients taking oral NSAIDs
Although it might be claimed that SRLB gel is a herbal remedy because it contains tinctures of herbal (n = 33; 16.0 mm VAS reduction) and relatively ineffective in patients receiving simple analgesics or no pain ingredients, it is officially registered as a homeopathic medicine in The Netherlands. Its 'homeopathicity' is medication (n = 51; 1.4 mm VAS reduction).
related to the nature rather than the dilution of its ingredients: its main ingredients are widely used in Discussion homeopathy for rheumatological conditions [20] , and it is manufactured according to the German Homeopathic The significantly higher average daily amount of gel used in the SRLB group may in part be explained by Pharmacopoeia.
We are aware of eight published controlled clinical the difference in tube aperture, but it can also be argued that more gel is likely to be used if it appears effective. trials of homeopathy for rheumatological conditions [21, 22] , two of them in osteoarthritis, one positive [22] The latter assumption was supported by an exploratory analysis in the SRLB group, which showed that patients and one negative [23] . Some authors have expressed doubts about the approwith a greater use of gel tended to have greater pain reduction (data not shown).
priateness of the use of NSAIDs in osteoarthritis because of its minor inflammatory component [24] . It has not Pain on palpation, scored as a single-joint Ritchie Index, was chosen in an attempt to obtain an independbeen established unequivocally that oral NSAIDs are more effective in controlling symptoms of osteoarthritis ently assessed, objective outcome parameter. In retrospect, there is no clear justification for its use because than simple analgesics [24, 25] . Empirical evidence suggests that many long-term NSAID users can be safely this parameter is not validated for use in osteoarthritis. When this study was designed (1992) there was no switched to simple analgesics without compromising their pain relief [26 ] . Strategies to take patients off oral international consensus on outcome measures for osteoarthritis. Even now, consensus is not complete.
NSAIDs are important because a reduction in mortality and morbidity from NSAID side-effects, as well as the However, a consensus is emerging [16 ] , and this study examined two of the three recommended outcome measuse of cheaper drugs, could lead to substantial savings. This study provides some evidence that the ures (pain and patient global assessment).
The concordance of the primary and secondary outhomeopathic gel used is more active than placebo. However, this cannot be proved from the study in its come measures adds further weight to the evidence for superior pain reduction in the SRLB group. present design. For this, an additional placebocontrolled trial in patients with no use of oral NSAIDs Although several precautions were taken, masking was inevitably imperfect in this trial. However, we felt (to be washed out if used) and limited use of paracetamol would be needed. A placebo-controlled, multicenthat the imperfect masking was unlikely to be a major cause of bias because both the patient and the investigtre trial of this nature (involving 214 patients with symptomatic primary osteoarthritis of the knee) was ators were assuming that two active products were being compared with the aim of showing equivalence.
recently conducted in The Netherlands and Belgium (in preparation). As mentioned above, an investigation of Although this is not formally recorded, very few eligible patients refused to enter the trial. The inclusion the role of the homeopathic gel in taking patients off oral NSAIDs is of particular clinical as well as economic criteria were such that few patients who might otherwise have been treated with a topical gel were excluded.
relevance. The meta-analysis by Moore et al. [7] 
